Drug Design of Antiobesity Carbonic Anhydrase Inhibitors (335 views)
Drug Des Of Zinc Enzyme Inhibitors (ISSN: 9780-4702, 9780-470275009), 2009; 66(DECEMBERSPEC.I): 241-254.
Export to BibTeX Export to EndNote
Paper type: Book Chapter,
Impact factor: 1.156, 5-year impact factor: 1.164
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84889494522&partnerID=40&md5=a2d479fa8baf89c8bf6b6e9e52387279
Keywords: Carbonic Anhydrases-New Targets In Obesity Treatment, Drug Design Of Antiobesity Carbonic Anhydrase Inhibitors, Zonisamide (zns)-Antiepileptic Drugs As Adjunctive Therapy For Refractory Partial Seizures, Diagnosis, Amfepramone, Biomag, Desobesi M, Dualid S, Fenproporex, Fluoxetine, Hipofagin S, Inibex S, Lipiblock, Mazindol, Moderine, Placebo, Plenty, Redulip, Rimonabant, Saciette, Sertraline, Sibus, Sibutramine, Sigran, Slenfig, Tetrahydrolipstatin, Unclassified Drug, Vazy, Article, Bariatric Surgery, Blood Clotting Disorder, Body Mass, Bulimia, Clinical Trial, Cognitive Therapy, Computer Assisted Tomography, Constipation, Defecation, Degenerative Disease, Depression, Diabetes Mellitus, Diastolic Blood Pressure, Disease Association, Dual Energy X Ray Absorptiometry, Echography, Fatty Liver, Flatulence, Gastrointestinal Symptom, Headache, Heart Palpitation, Heart Rate, Human, Impedance, Insomnia, Kinesiotherapy, Mortality, Nuclear Magnetic Resonance Imaging, Prevalence, Side Effect, Sleep Apnea Syndrome, Systolic Blood Pressure, Unspecified Side Effect, Xerostomia,
Affiliations:
*** IBB - CNR ***
Istituto di Biostrutture e Bioimmagini-CNR, Via Mezzocannone 16, 80134 Naples, Italy
Laboratorio di Chimica Bioinorganica, Università degli Studi di Firenze, Polo Scientifico, Via della Lastruccia 3, I-50019 Sesto Fiorentino (Firenze), Italy
rea de Endocrinologie, Faculdade de Medicina Da Universidade de S o Paulo (FMUSP), Brazil
Grupo de Obesidade e S ndrome Metab lica, Hospital Das Cl nicas (HC-FMUSP), Liga de Obesidade Infantil da FMUSP, Brazil
Laborat rio de Carboidratos e Radioimunoensaio (LIM 18) da FMUSP, Brazil
References:
Friedman, J.M., A war on obesity, not the obese (2003) Science, 299, pp. 856-85
Hill, J.O., Wyatt, H.R., Reed, G.W., Peters, J.C., Obesity and the environment: where do we go from here? (2003) Science, 299, pp. 853-855
Ioannides-Demos, L.L., Proietto, J., Tonkin, A.M., McNeil, J.J., Safety of drug therapies used for weight loss and treatment of obesity (2006) Drug Saf., 29, pp. 277-302
Campfield, L.A., Smith, F.J., Burn, P., Strategies and potential molecular targets for obesity treatment (1998) Science, 280, pp. 1383-1387
Van Gaal, L., Mertens, I., Effects of obesity on cardiovascular systems and blood pressure control, digestive disease and cancer (1998), pp. 205-225. , In Clinical Obesity
Blackwell: OxfordAvenell, A., Broom, J., Brown, T.J., Poobalan, A., Aucott, L., Stearns, S.C., Smith, W.C., Grant, A.M., Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement (2004) Health Technol. Assess., 8, pp. 1-182
Lau, D.C.W., Synopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children (2007) CMAJ, 176, pp. 1103-1106
Leibel, R.L., Rosenbaum, M., Hirsch, J., Changes in energy expenditure resulting from altered body weight (1995) N. Engl. J. Med., 332, pp. 621-628
Halford, J.C.G., Pharmacotherapy for obesity (2006) Appetite, 46, pp. 6-10
Chaput, J.P., Tremblay, A., Current and novel approaches to the drug therapy of obesity (2006) Eur. J. Clin. Pharmacol., 62, pp. 793-803
Cheetham, S.C., Jackson, H.C., Vickers, S.P., Dickinson, K., Jones, R.B., Heal, D.J., Novel targets for the treatment of obesity: a review of progress (2004) Drug Discov. Today Ther. Strateg., 1, pp. 227-235
Gadde, K.M., Endocannabinoid receptor antagonists and other emerging pharmacological strategies for weight reduction (2005) Curr. Drug Targets Cardiovasc. Haematol. Disord., 5, pp. 549-556
Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J., Rosenstock, J., RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial (2006) JAMA, 295, pp. 761-775
Bays, H., Dujovne, C., Pharmacotherapy of obesity: currently marketed and upcoming agents (2002) Am. J. Cardiovasc. Drugs, 2, pp. 245-253
Mcnelly, W., Goa Sibutramine, K.L., A review of its contribution to the management of obesity (1998) Drugs, 56, pp. 1093-1124
Lean, M.E., How does sibutramine work? (2001) Int. J. Obes. Relat. Metab. Disord., 25 (SUPPL. 4), pp. S8-S11
Bray, G.A., Blackburn, G.L., Ferguson, J.M., Greenway, F.L., Jain, A.K., Mendel, C.M., Mendels, J., Seaton, T.B., Sibutramine produces dose-related weight loss (1999) Obes. Res., 7, pp. 189-198
James, W.P., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rossner, S., Saris, W.H., Val Gaal, L.F., Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance (2000) Lancet, 356, pp. 2119-2125
Weibel, E.K., Hadvary, P., Hochuly, E., Kupfer, E., Lengsfeld, H., Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini, I: producing organism, fermentation, isolation and biological activity (1987) J. Antibiot., 40, pp. 1081-1085. , Tokyo
Sidhaye, A., Cheskin, L.J., Pharmacologic treatment of obesity (2006) Adv. Psychosom. Med., 27, pp. 42-52
Davidson, M.H., Hauptman, J., DiGirolamo, M., Foreyt, J.P., Halsted, C.H., Heber, D., Heimburger, D.C., Heymsfield, S.B., Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat (1999) JAMA, 281, pp. 235-242
Hollander, P.A., Elbein, S.C., Hirsch, I.B., Kelley, D., McGill, J., Taylor, T., Weiss, S.R., Hauptman, J., Role of orlistat in the treatment of obese patients with type 2 diabetes (1998) Diabetes Care, 21, pp. 1288-1294
Rössner, S., Sjöström, L., Noack, R., Meinders, A.E., Noseda, G., Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group (2000) Obes. Res., 8, pp. 49-61
Rucker, D., Padwall, R., Li, S.K., Curioni, C., Lau, D.C., Long term pharmacotherapy for obesity and overweight: updated meta-analysis (2007) BMJ, 335, pp. 1194-1199
Bray, G.A., Ryan, D.H., Drug treatment of the overweight patient (2007) Gastroenterology, 132, pp. 2239-2252
Padwal, R.S., Majumdar, S.R., Drug treatments for obesity: orlistat, sibutramine, and rimonabant (2007) Lancet, 369, pp. 71-77
Bays, H.E., Current and investigational antiobesity agents and obesity therapeutic treatment targets (2004) Obes. Res., 12, pp. 1197-1211
Supuran, C.T., Carbonic anhydrases: novel therapeutic applications for inhibitors and activators (2008) Nat. Rev. Drug Discov., 7, pp. 168-181
Supuran, C.T., Scozzafava, A., Casini, A., Carbonic anhydrase inhibitors (2003) Med. Res. Rev., 23, pp. 146-189
Tripp, B.C., Smith, K., Ferry, J.G., Carbonic anhydrase: new insights for an ancient enzyme (2001) J. Biol. Chem., 276, pp. 48615-48618
Whittington, D.A., Waheed, A., Ulmasov, B., Shah, G.N., Grubb, J.H., Sly, W.S., Christianson, D.W., Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells (2001) Proc. Natl. Acad. Sci. USA, 98, pp. 9545-9550
Duda, D.M., Tu, C., Fisher, S.Z., An, H., Yoshioka, C., Govindasamy, L., Laipis, P.J., McKenna, R., Human carbonic anhydrase III:structural and kinetic study of catalysis and proton transfer (2005) Biochemistry, 44, pp. 10046-10053
Eriksson, A.E., Jones, T.A., Liljas, A., Refined structure of human carbonic anhydrase II at 2.0Å resolution (1988) Proteins, 4, pp. 274-282
Kannan, K.K., Ramanadham, M., Jones, T.A., Structure, refinement, and function of carbonic anhydrase isozymes: refinement of human carbonic anhydrase I (1984) Ann. N. Y. Acad. Sci., 429, pp. 49-60
Stams, T., Nair, S.K., Okuyama, T., Waheed, A., Sly, W.S., Christianson, D.W., Crystal structure of the secretory form of membrane-associated human carbonic anhydrase IV at 2.8Å resolution (1996) Proc. Natl. Acad. Sci. USA, 93, pp. 13589-13594
Di Fiore, A., Monti, S.M., Hilvo, M., Parkkila, S., Romano, V., Scaloni, A., Pedone, C., De Simone, G., Crystal structure of human carbonic anhydrase XIII and its complex with acetazolamide (2009) Proteins, 74, pp. 164-175
Dodgson, S.J., Inhibition of mitochondrial carbonic anhydrase: a discrepancy examined (1987) J. Appl. Physiol., 63, pp. 2134-2141
Dodgson, S.J., Cherian, K., Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis (1989) Am. J. Physiol., 257, pp. E791-E796
Spencer, I.M., Hargreaves, I., Chegwidden, W.R., Effect of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust (1988) Biochem. Soc. Trans., 16, pp. 973-974
Chegwidden, W.R., Spencer, I.M., Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus (1996) Comp. Biochem. Physiol., 115 B, pp. 247-254
Chegwidden, W.R., Dodgson, S.J., Spencer, I.M., The roles of carbonic anhydrase in metabolism, cell growth and cancer in animals (2000), pp. 343-363. , In The Carbonic Anhydrases: New Horizons
Birkhäuser Verlag: BaselLynch, C.J., Fox, H., Hazen, S.A., Stanley, B.A., Dodgson, S.J., Lanoue, K.F., Role of hepatic carbonic anhydrase in de novo lipogenesis (1995) Biochem. J., 310, pp. 197-202
Hazen, S.A., Waheed, A., Sly, W.S., Lanoue, K.F., Lynch, C.J., Differentiation-dependent expression ofCAVand the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes (1996) FASEB J., 10, pp. 481-490
Atwood, P.V., The structure and mechanism of action of pyruvate carboxylase (1995) Int. J. Biochem. Cell Biol., 27, pp. 231-249
Alldred, J.B., Reilly, K.E., Short-term regulation of acetyl CoA carboxylase in tissues of higher animals (1997) Prog. Lipid Res., 35, pp. 371-385
Forster, R.E., Dodgson, S.J., Membrane transport and provision of substrates for carbonic anhydrase in vertebrates (2000), pp. 263-280. , In The Carbonic Anhydrases: New Horizons
CRC Press: Boca Raton, FLShank, R.P., Gardocki, J.F., Vaught, J.L., Davis, C.B., Schupsky, J.J., Raffa, R.B., Dodgson, S.J., Maryanoff, B.E., Topiramate: preclinical evaluation of structurally novel anticonvulsant. Eopiramate: preclinical evaluation of structurally novel anticonvulsant (1994) Epilepsia, 35, pp. 450-460
Edmonds, H.L., Jiang, Y.D., Zhang, P.Y., Shank, R.P., Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy (1996) Life Sci., 59, pp. PL127-PL131
Stringer, J.L., A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat (2000) Epilepsy Res., 40, pp. 147-153
Sabers, A., Gram, L., Newer anticonvulsants: comparative review of drug interactions and adverse effects (2000) Drugs, 60, pp. 23-33
Bourgeois, B.F.D., Pharmacokinetics and pharmacodynamics of topiramate (2000) J. Child Neurol., 15, pp. S27-S30
Bialer, M., Johannessen, S.I., Kupferberg, H.J., Levy, R.H., Loiseau, P., Perucca, E., Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (2001) Epilepsy Res., 43, pp. 11-58
Gordon, A., Price, L.H., Mood stabilization and weight loss with topiramate (1999) Am. J. Psychiatry, 156, pp. 968-969
Casini, A., Antel, J., Abbate, F., Scozzafava, A., David, S., Waldeck, H., Schäfer, S., Supuran, C.T., Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV (2003) Bioorg. Med. Chem. Lett., 13, pp. 841-845
Vitale, R.M., Pedone, C., Amodeo, P., Antel, J., Wurl, M., Scozzafava, A., Supuran, C.T., De Simone, G., Carbonic anhydrase inhibitors: molecular modeling study for the interaction of zonisamide and topiramate with isozyme VA (2007) Bioorg. Med. Chem., 15, pp. 4152-4158
Zareba, G., Zonisamide: review of its use in epilepsy therapy. Donisamide: review of its use in epilepsy therapy (2005) Drug Today (Barc.), 41, pp. 589-597
Kim, C.S., Zonisamide effective for weight loss in women (2003) J. Fam. Pract., 52, pp. 600-601
Jennings, J.E., Zonisamide use in obesity and eating disorders (2003), p. 18. , PCT International Application WO 2003092682De Simone, G., Di Fiore, A., Menchise, V., Pedone, C., Antel, J., Casini, A., Scozzafava, A., Supuran, C.T., Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies (2005) Bioorg. Med. Chem. Lett., 15, pp. 2315-2320
Masuda, Y., Karasawa, T., Inhibitory effect of zonisamide on human carbonic anhydrase in vitro (1993) Arzneimittelforschung, 43, pp. 416-418
Gadde, K.M., Franciscy, D.M., Wagner, H.R., Krishnan, K.R., Zonisamide for weight loss in obese adults: a randomized controlled trial (2003) JAMA, 289, pp. 1820-1825
Seidell, J. C., Epidemiology: Definition and Classification of Obesity (1998) Clinical Obesity, pp. 1-17. , Kopelman amp
Stock MJ Eds, Blackwell Science, London, p
http: //www. cdc. gov/obesity/childhood/defining. htmlFarooqi, I. S., Monogenic human obesity (2008) Front Horm Res, 36, pp. 1-11
Danford, L. C., Schoeller, D. A., Kushner, R. F., Comparison of two bioeletrical impedance models for total body water measurements in children (1992) Ann Hum Biol, 19, pp. 603-607
Sims, E. A. H., Berchtold, P., Obesity and hypertension: Mechanisms and implications for management (1982) JAMA, 247, pp. 49-52
Bray, G. A., Complications of obesity (1985) Ann Intern Med, 103, pp. 1052-1062
Garrison, R. J., Kannel, W. B., Stokes III, J., Castelli, W. P., Incidence and precursors of hypertension in young adults: The Framingham Offspring Study (1987) Prev Med, 16, pp. 235-251
Kissebah, A. H., Peiris, A. N., Biology of regional body fat distribution. Relationship to non-insulin-dependent diabetes mellitus (1989) Diab Metab Rev, 15, pp. 83-109
Vague, J., La diff renciation sexuelle, facteur d terminant des formes d'Ob sit. (1947) Presse Med, 30, pp. 339-340
Despr s, J. P., Prud'homme, D., Pouliot, M. C., Estimation of deep abdominal adipose-tissue accumulation from simple anthropometric measurements in men (1991) Am J Clin Nutr, 54, pp. 471-477
Sj str m, L., Kvist, H., Cederblad, A., Tylen, U., Determination of total adipose tissue and body fat in women by computed tomography, 4OK, and tritium (1986) Am J Physiol, 250, pp. E736-E745
Kissebah, A. H., Krakower, G. R., Regional adiposity and morbidity (1994) Physiolog Rev, 74, pp. 761-811
Reaven, G. M., Role of insulin resistance in human disease (1988) Diabetes, 37, pp. 1595-1607
Tchernof, A., Lamarche, B., The dense LDL phenotipe: Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men (1996) Diabetes Care, 19, pp. 629-637
Simopoulos, A., Van Italie, T., Body weight, health and longevity (1984) Ann Intern Med, 100, pp. 285-295
Manson, J., Stampfer, M., Body weight and longevity. A reassessment (1987) JAMA, 257, pp. 353-358
Garn, S., Leonard, W., Hawthorne, V., Three limitations of the body mass index (1986) Am J Clin Nutr, 44, pp. 996-997
Feinleb, M., Epidemiology of obesity in relation to health hazards (1985) Ann Intern Med, 103, pp. 1019-1024
Robinson, S., Franks, S., Obesity, Infertility, Contraception and Pregnancy (1998) Clinical Obesity, pp. 226-247. , Kopelman amp
Manson, J., Willett, W., Body weight and mortality among women (1995) N Engl J Med, 333, pp. 677-685
Kannel, W., D'Agostino, R., Belanger, A., Update on fibrinogen as a cardiovascular risk factor (1992) Ann Epidemiol, 2, pp. 457-466
Ditschunneit, H., Flechtner-Mors, M., Adler, G., Fibrinogen in obesity before and after weight reduction (1995) Obesity Res, 3, pp. 43-48
Van Gaal, L., Zhang, A., Steijaert, M., De Leeuw, I., Human obesity: From lipid abnormalities to lipid oxidation (1995) Int J Obesity, 19 (SUPPL. 3), pp. S21-S26
Folsom, A., Burke, G., Relation of body fatness and its distribution to cardiovascular risk factors in young black and whites. The role of insulin (1989) Am J Epidemiol, 130, pp. 911-924
Friedman, G., Selby, J., Precursors of essential hypertension: Body weight, alcohol and salt use, and parental history of hypertension (1988) Prev Med, 17, pp. 387-402
de Sousa, A. G., Cercato, C., Mancini, M. C., Halpern, A., Obesity and obstructive sleep apnea-hypopnea syndrome (2008) Obes Rev, 9 (4), pp. 340-354
Barbara, L., Sama, C., Labate, A. M. M., A population study on the prevalence of gallstone disease: The Sirmione study (1987) Hepatol, 7, pp. 913-917
Clain, D., Lefkowitch, J., Fatty liver disease in morbid obesity (1987) Gastroenterol Clin North Am, 16, pp. 239-252
Swanson, C., Brinton, L., Taylor, P., Licitra, L., Ziegler, R., Schairer, C., Body size and breast cancer risk assessed in women participating in the breast cancer detection demonstration project (1989) Am J Epidemiol, 130, pp. 1133-1141
Austin, H., Austin, J., Partridge, E., Endometrial cancer, obesity, and body fat distribution (1991) Cancer Res, 51, pp. 568-572
Demark-Wahnefried, W., Paulson, D., Body dimension differences in men with and without prostate cancer (1992) J Nat Cancer Inst, 84, pp. 1363-1364
Young, T., Palta, M., Dempsey, J., Skatrud, J., Webber, S., Badr, S., The occurence of sleep disordered breathing among middle aged adults (1993) N Engl J Med, 328, pp. 1230-1235
Young, T., Finn, L., HIa, M., Morgan, B., Palta, M., Snoring as Part of a Dose-Response Relationship Between Sleep-Disordered Breathing and Blood Pressure (1996) Sleep, 19 (10), pp. S202-S206
Mancini, M. C., Aloe, F., Obesidade, Apn ia Obstrutiva do Sono e Dist rbios Respiratorios (1998) Obesidade, Halpern A, Matos AFG, Suplicy H, Mancini MC & Zanella MT, pp. 153-170. , Ed. Lemos, S o Paulo
Cole, T. J., Freeman, J. V., Preece, M. A., Body mass index reference curves for the UK, 1990 (1995) Arch Dis Child, 73, pp. 25-29
Chan, J. M., Stampfer, M. J., Ribb, E. M., Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in man (1994) Diabetes Care, 17, pp. 961-969
Finer, N., Clinical Assessment, Investigation and Principles of Management: Realistic Weight Goals (1998) Clinical Obesity, pp. 350-376. , Kopelman amp
Wilson, G. T., Fairbu, rn, C. G., Cognitive treatments for eating disorders (1993) J Consulting Clin Psychol, 61, pp. 261-269
Tremblay, A., Buemann, B., Exercise-training, macronutrient balance and body weight control (1995) Int J Obesity, 19, pp. 79-86
Tremblay, A., Simoneau, J., Bouchard, C., Impact of exercise intensity on body fatness and skeletal muscle metabolism (1994) Metabolism, 43, pp. 814-818
(1996) Weighing the Options: Criteria for Evaluating Weight-Management Programs, , Thomas PR ed, National Academy Press: Washington DC
Long-term pharmacotherapy in the management of obesity (1996) JAMA, 276, pp. 1907-1915. , National Task Force on the Prevention and Treatment of Obesity
Tratamento, M. M. C., Farmacologico da Obesidade: Medicamentos Calorig nicos (1998) Obesidade, Halpern A, Mates AFG, Suplicy H, Mancini MC & Zanella MT, pp. 297-303. , Ed. Lemos, S o Paulo, pp
Kernan, W. N., Viscoli, C. M., Brass, L. M., Phenylpropanolamine and the Risk of Hemorrhagic Stroke (2000) N Engl J Med, 343, pp. 1826-1832
Cercato, C., Roizenblatt, V. A., Lean a, C. C., Segal, A., Lopes Filho, A. P., Mancini, M. C., Halpern, A., A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects (2009) Int J Obes, 33 (8), pp. 857-865
Connoley, I. P., Heal, D. J., Stock, M. J., A study in rats of the effects of sibutramine on food intake and thermogenesis (1995) Br J Pharmacol, 114 (SUPPL.). , 388P
Halford, J. C. G., Heal, D. J., Blundell, J. E., Effects in the rat of sibutramine on food intake and the behavioural satiety sequence (1995) Br J Pharmacol, 114 (SUPPL.). , 387P
Connoley, I. P., Uu, Y. -L., Frost, I., Thermogenic effects of sibutramine and its metabolites (1999) Br J Pharmacol, 126, pp. 1487-1495
Guerciolini, R., Mode of action of orlistat (1997) Int J Obes, 21 (SUPPL. 3), pp. S12-S23
Zhi, J., Melia, A. T., Funk, C., Metabolic profile of minimally absorbed orlistat in obese/overweight volunteers (1996) J Clin Pharmacol, 36, pp. 1006-1011
Halpern, A., Mancini, M. C., Diabesity: Are weight loss medications effective? (2005) Treat Endocrinol, 4 (2), pp. 65-74
Bray, G. A., Blackburn, G. L., Ferguson, J. M., Sibutramine produces doserelated weight loss (1999) Obesity Res, 7, pp. 189-198
Sj str m, L., Rissanen, A., Andersen, T., Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients (1998) Lancet, 352, pp. 167-172
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Role of orlistat in the treatment of obese patients with type 2 diabetes (1998) Diabetes Care, 21, pp. 1288-1294
Davidson, M. H., Hauptman, J., DiGirolamo, M., Weight control and risk factor reduction In obese subjects treated for 2 years with orlistat (1999) JAMA, 281, pp. 235-242
Garrido Jr., A. B., Matielli, J. D., Tratamento Cir rgico do Paciente Obeso (2009) Obesidade e S ndrome Metab lica para o Cl nico, pp. 267-290. , Halpern A, Mancini M. Ed. Roca, S o Paulo, pp
Sj str m, L., Narbro, K., Sj str m, C. D., Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects (2007) N Engl J Med, 357 (8), p. 23. , 741-52
Sj str m, L., Gummesson, A., Sj str m, C. D., Swedish Obese Subjects Study. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): A prospective, controlled intervention trial (2009) Lancet Oncol, 10 (7), pp. 653-662
Drug Des Of Zinc Enzyme Inhibitors (ISSN: 9780-4702, 9780-470275009), 2009; 66(DECEMBERSPEC.I): 241-254.
Export to BibTeX Export to EndNote
Paper type: Book Chapter,
Impact factor: 1.156, 5-year impact factor: 1.164
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84889494522&partnerID=40&md5=a2d479fa8baf89c8bf6b6e9e52387279
Keywords: Carbonic Anhydrases-New Targets In Obesity Treatment, Drug Design Of Antiobesity Carbonic Anhydrase Inhibitors, Zonisamide (zns)-Antiepileptic Drugs As Adjunctive Therapy For Refractory Partial Seizures, Diagnosis, Amfepramone, Biomag, Desobesi M, Dualid S, Fenproporex, Fluoxetine, Hipofagin S, Inibex S, Lipiblock, Mazindol, Moderine, Placebo, Plenty, Redulip, Rimonabant, Saciette, Sertraline, Sibus, Sibutramine, Sigran, Slenfig, Tetrahydrolipstatin, Unclassified Drug, Vazy, Article, Bariatric Surgery, Blood Clotting Disorder, Body Mass, Bulimia, Clinical Trial, Cognitive Therapy, Computer Assisted Tomography, Constipation, Defecation, Degenerative Disease, Depression, Diabetes Mellitus, Diastolic Blood Pressure, Disease Association, Dual Energy X Ray Absorptiometry, Echography, Fatty Liver, Flatulence, Gastrointestinal Symptom, Headache, Heart Palpitation, Heart Rate, Human, Impedance, Insomnia, Kinesiotherapy, Mortality, Nuclear Magnetic Resonance Imaging, Prevalence, Side Effect, Sleep Apnea Syndrome, Systolic Blood Pressure, Unspecified Side Effect, Xerostomia,
Affiliations:
*** IBB - CNR ***
Istituto di Biostrutture e Bioimmagini-CNR, Via Mezzocannone 16, 80134 Naples, Italy
Laboratorio di Chimica Bioinorganica, Università degli Studi di Firenze, Polo Scientifico, Via della Lastruccia 3, I-50019 Sesto Fiorentino (Firenze), Italy
rea de Endocrinologie, Faculdade de Medicina Da Universidade de S o Paulo (FMUSP), Brazil
Grupo de Obesidade e S ndrome Metab lica, Hospital Das Cl nicas (HC-FMUSP), Liga de Obesidade Infantil da FMUSP, Brazil
Laborat rio de Carboidratos e Radioimunoensaio (LIM 18) da FMUSP, Brazil
References:
Friedman, J.M., A war on obesity, not the obese (2003) Science, 299, pp. 856-85
Hill, J.O., Wyatt, H.R., Reed, G.W., Peters, J.C., Obesity and the environment: where do we go from here? (2003) Science, 299, pp. 853-855
Ioannides-Demos, L.L., Proietto, J., Tonkin, A.M., McNeil, J.J., Safety of drug therapies used for weight loss and treatment of obesity (2006) Drug Saf., 29, pp. 277-302
Campfield, L.A., Smith, F.J., Burn, P., Strategies and potential molecular targets for obesity treatment (1998) Science, 280, pp. 1383-1387
Van Gaal, L., Mertens, I., Effects of obesity on cardiovascular systems and blood pressure control, digestive disease and cancer (1998), pp. 205-225. , In Clinical Obesity
Blackwell: OxfordAvenell, A., Broom, J., Brown, T.J., Poobalan, A., Aucott, L., Stearns, S.C., Smith, W.C., Grant, A.M., Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement (2004) Health Technol. Assess., 8, pp. 1-182
Lau, D.C.W., Synopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children (2007) CMAJ, 176, pp. 1103-1106
Leibel, R.L., Rosenbaum, M., Hirsch, J., Changes in energy expenditure resulting from altered body weight (1995) N. Engl. J. Med., 332, pp. 621-628
Halford, J.C.G., Pharmacotherapy for obesity (2006) Appetite, 46, pp. 6-10
Chaput, J.P., Tremblay, A., Current and novel approaches to the drug therapy of obesity (2006) Eur. J. Clin. Pharmacol., 62, pp. 793-803
Cheetham, S.C., Jackson, H.C., Vickers, S.P., Dickinson, K., Jones, R.B., Heal, D.J., Novel targets for the treatment of obesity: a review of progress (2004) Drug Discov. Today Ther. Strateg., 1, pp. 227-235
Gadde, K.M., Endocannabinoid receptor antagonists and other emerging pharmacological strategies for weight reduction (2005) Curr. Drug Targets Cardiovasc. Haematol. Disord., 5, pp. 549-556
Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J., Rosenstock, J., RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial (2006) JAMA, 295, pp. 761-775
Bays, H., Dujovne, C., Pharmacotherapy of obesity: currently marketed and upcoming agents (2002) Am. J. Cardiovasc. Drugs, 2, pp. 245-253
Mcnelly, W., Goa Sibutramine, K.L., A review of its contribution to the management of obesity (1998) Drugs, 56, pp. 1093-1124
Lean, M.E., How does sibutramine work? (2001) Int. J. Obes. Relat. Metab. Disord., 25 (SUPPL. 4), pp. S8-S11
Bray, G.A., Blackburn, G.L., Ferguson, J.M., Greenway, F.L., Jain, A.K., Mendel, C.M., Mendels, J., Seaton, T.B., Sibutramine produces dose-related weight loss (1999) Obes. Res., 7, pp. 189-198
James, W.P., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rossner, S., Saris, W.H., Val Gaal, L.F., Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance (2000) Lancet, 356, pp. 2119-2125
Weibel, E.K., Hadvary, P., Hochuly, E., Kupfer, E., Lengsfeld, H., Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini, I: producing organism, fermentation, isolation and biological activity (1987) J. Antibiot., 40, pp. 1081-1085. , Tokyo
Sidhaye, A., Cheskin, L.J., Pharmacologic treatment of obesity (2006) Adv. Psychosom. Med., 27, pp. 42-52
Davidson, M.H., Hauptman, J., DiGirolamo, M., Foreyt, J.P., Halsted, C.H., Heber, D., Heimburger, D.C., Heymsfield, S.B., Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat (1999) JAMA, 281, pp. 235-242
Hollander, P.A., Elbein, S.C., Hirsch, I.B., Kelley, D., McGill, J., Taylor, T., Weiss, S.R., Hauptman, J., Role of orlistat in the treatment of obese patients with type 2 diabetes (1998) Diabetes Care, 21, pp. 1288-1294
Rössner, S., Sjöström, L., Noack, R., Meinders, A.E., Noseda, G., Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group (2000) Obes. Res., 8, pp. 49-61
Rucker, D., Padwall, R., Li, S.K., Curioni, C., Lau, D.C., Long term pharmacotherapy for obesity and overweight: updated meta-analysis (2007) BMJ, 335, pp. 1194-1199
Bray, G.A., Ryan, D.H., Drug treatment of the overweight patient (2007) Gastroenterology, 132, pp. 2239-2252
Padwal, R.S., Majumdar, S.R., Drug treatments for obesity: orlistat, sibutramine, and rimonabant (2007) Lancet, 369, pp. 71-77
Bays, H.E., Current and investigational antiobesity agents and obesity therapeutic treatment targets (2004) Obes. Res., 12, pp. 1197-1211
Supuran, C.T., Carbonic anhydrases: novel therapeutic applications for inhibitors and activators (2008) Nat. Rev. Drug Discov., 7, pp. 168-181
Supuran, C.T., Scozzafava, A., Casini, A., Carbonic anhydrase inhibitors (2003) Med. Res. Rev., 23, pp. 146-189
Tripp, B.C., Smith, K., Ferry, J.G., Carbonic anhydrase: new insights for an ancient enzyme (2001) J. Biol. Chem., 276, pp. 48615-48618
Whittington, D.A., Waheed, A., Ulmasov, B., Shah, G.N., Grubb, J.H., Sly, W.S., Christianson, D.W., Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells (2001) Proc. Natl. Acad. Sci. USA, 98, pp. 9545-9550
Duda, D.M., Tu, C., Fisher, S.Z., An, H., Yoshioka, C., Govindasamy, L., Laipis, P.J., McKenna, R., Human carbonic anhydrase III:structural and kinetic study of catalysis and proton transfer (2005) Biochemistry, 44, pp. 10046-10053
Eriksson, A.E., Jones, T.A., Liljas, A., Refined structure of human carbonic anhydrase II at 2.0Å resolution (1988) Proteins, 4, pp. 274-282
Kannan, K.K., Ramanadham, M., Jones, T.A., Structure, refinement, and function of carbonic anhydrase isozymes: refinement of human carbonic anhydrase I (1984) Ann. N. Y. Acad. Sci., 429, pp. 49-60
Stams, T., Nair, S.K., Okuyama, T., Waheed, A., Sly, W.S., Christianson, D.W., Crystal structure of the secretory form of membrane-associated human carbonic anhydrase IV at 2.8Å resolution (1996) Proc. Natl. Acad. Sci. USA, 93, pp. 13589-13594
Di Fiore, A., Monti, S.M., Hilvo, M., Parkkila, S., Romano, V., Scaloni, A., Pedone, C., De Simone, G., Crystal structure of human carbonic anhydrase XIII and its complex with acetazolamide (2009) Proteins, 74, pp. 164-175
Dodgson, S.J., Inhibition of mitochondrial carbonic anhydrase: a discrepancy examined (1987) J. Appl. Physiol., 63, pp. 2134-2141
Dodgson, S.J., Cherian, K., Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis (1989) Am. J. Physiol., 257, pp. E791-E796
Spencer, I.M., Hargreaves, I., Chegwidden, W.R., Effect of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust (1988) Biochem. Soc. Trans., 16, pp. 973-974
Chegwidden, W.R., Spencer, I.M., Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus (1996) Comp. Biochem. Physiol., 115 B, pp. 247-254
Chegwidden, W.R., Dodgson, S.J., Spencer, I.M., The roles of carbonic anhydrase in metabolism, cell growth and cancer in animals (2000), pp. 343-363. , In The Carbonic Anhydrases: New Horizons
Birkhäuser Verlag: BaselLynch, C.J., Fox, H., Hazen, S.A., Stanley, B.A., Dodgson, S.J., Lanoue, K.F., Role of hepatic carbonic anhydrase in de novo lipogenesis (1995) Biochem. J., 310, pp. 197-202
Hazen, S.A., Waheed, A., Sly, W.S., Lanoue, K.F., Lynch, C.J., Differentiation-dependent expression ofCAVand the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes (1996) FASEB J., 10, pp. 481-490
Atwood, P.V., The structure and mechanism of action of pyruvate carboxylase (1995) Int. J. Biochem. Cell Biol., 27, pp. 231-249
Alldred, J.B., Reilly, K.E., Short-term regulation of acetyl CoA carboxylase in tissues of higher animals (1997) Prog. Lipid Res., 35, pp. 371-385
Forster, R.E., Dodgson, S.J., Membrane transport and provision of substrates for carbonic anhydrase in vertebrates (2000), pp. 263-280. , In The Carbonic Anhydrases: New Horizons
CRC Press: Boca Raton, FLShank, R.P., Gardocki, J.F., Vaught, J.L., Davis, C.B., Schupsky, J.J., Raffa, R.B., Dodgson, S.J., Maryanoff, B.E., Topiramate: preclinical evaluation of structurally novel anticonvulsant. Eopiramate: preclinical evaluation of structurally novel anticonvulsant (1994) Epilepsia, 35, pp. 450-460
Edmonds, H.L., Jiang, Y.D., Zhang, P.Y., Shank, R.P., Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy (1996) Life Sci., 59, pp. PL127-PL131
Stringer, J.L., A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat (2000) Epilepsy Res., 40, pp. 147-153
Sabers, A., Gram, L., Newer anticonvulsants: comparative review of drug interactions and adverse effects (2000) Drugs, 60, pp. 23-33
Bourgeois, B.F.D., Pharmacokinetics and pharmacodynamics of topiramate (2000) J. Child Neurol., 15, pp. S27-S30
Bialer, M., Johannessen, S.I., Kupferberg, H.J., Levy, R.H., Loiseau, P., Perucca, E., Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (2001) Epilepsy Res., 43, pp. 11-58
Gordon, A., Price, L.H., Mood stabilization and weight loss with topiramate (1999) Am. J. Psychiatry, 156, pp. 968-969
Casini, A., Antel, J., Abbate, F., Scozzafava, A., David, S., Waldeck, H., Schäfer, S., Supuran, C.T., Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV (2003) Bioorg. Med. Chem. Lett., 13, pp. 841-845
Vitale, R.M., Pedone, C., Amodeo, P., Antel, J., Wurl, M., Scozzafava, A., Supuran, C.T., De Simone, G., Carbonic anhydrase inhibitors: molecular modeling study for the interaction of zonisamide and topiramate with isozyme VA (2007) Bioorg. Med. Chem., 15, pp. 4152-4158
Zareba, G., Zonisamide: review of its use in epilepsy therapy. Donisamide: review of its use in epilepsy therapy (2005) Drug Today (Barc.), 41, pp. 589-597
Kim, C.S., Zonisamide effective for weight loss in women (2003) J. Fam. Pract., 52, pp. 600-601
Jennings, J.E., Zonisamide use in obesity and eating disorders (2003), p. 18. , PCT International Application WO 2003092682De Simone, G., Di Fiore, A., Menchise, V., Pedone, C., Antel, J., Casini, A., Scozzafava, A., Supuran, C.T., Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies (2005) Bioorg. Med. Chem. Lett., 15, pp. 2315-2320
Masuda, Y., Karasawa, T., Inhibitory effect of zonisamide on human carbonic anhydrase in vitro (1993) Arzneimittelforschung, 43, pp. 416-418
Gadde, K.M., Franciscy, D.M., Wagner, H.R., Krishnan, K.R., Zonisamide for weight loss in obese adults: a randomized controlled trial (2003) JAMA, 289, pp. 1820-1825
Seidell, J. C., Epidemiology: Definition and Classification of Obesity (1998) Clinical Obesity, pp. 1-17. , Kopelman amp
Stock MJ Eds, Blackwell Science, London, p
http: //www. cdc. gov/obesity/childhood/defining. htmlFarooqi, I. S., Monogenic human obesity (2008) Front Horm Res, 36, pp. 1-11
Danford, L. C., Schoeller, D. A., Kushner, R. F., Comparison of two bioeletrical impedance models for total body water measurements in children (1992) Ann Hum Biol, 19, pp. 603-607
Sims, E. A. H., Berchtold, P., Obesity and hypertension: Mechanisms and implications for management (1982) JAMA, 247, pp. 49-52
Bray, G. A., Complications of obesity (1985) Ann Intern Med, 103, pp. 1052-1062
Garrison, R. J., Kannel, W. B., Stokes III, J., Castelli, W. P., Incidence and precursors of hypertension in young adults: The Framingham Offspring Study (1987) Prev Med, 16, pp. 235-251
Kissebah, A. H., Peiris, A. N., Biology of regional body fat distribution. Relationship to non-insulin-dependent diabetes mellitus (1989) Diab Metab Rev, 15, pp. 83-109
Vague, J., La diff renciation sexuelle, facteur d terminant des formes d'Ob sit. (1947) Presse Med, 30, pp. 339-340
Despr s, J. P., Prud'homme, D., Pouliot, M. C., Estimation of deep abdominal adipose-tissue accumulation from simple anthropometric measurements in men (1991) Am J Clin Nutr, 54, pp. 471-477
Sj str m, L., Kvist, H., Cederblad, A., Tylen, U., Determination of total adipose tissue and body fat in women by computed tomography, 4OK, and tritium (1986) Am J Physiol, 250, pp. E736-E745
Kissebah, A. H., Krakower, G. R., Regional adiposity and morbidity (1994) Physiolog Rev, 74, pp. 761-811
Reaven, G. M., Role of insulin resistance in human disease (1988) Diabetes, 37, pp. 1595-1607
Tchernof, A., Lamarche, B., The dense LDL phenotipe: Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men (1996) Diabetes Care, 19, pp. 629-637
Simopoulos, A., Van Italie, T., Body weight, health and longevity (1984) Ann Intern Med, 100, pp. 285-295
Manson, J., Stampfer, M., Body weight and longevity. A reassessment (1987) JAMA, 257, pp. 353-358
Garn, S., Leonard, W., Hawthorne, V., Three limitations of the body mass index (1986) Am J Clin Nutr, 44, pp. 996-997
Feinleb, M., Epidemiology of obesity in relation to health hazards (1985) Ann Intern Med, 103, pp. 1019-1024
Robinson, S., Franks, S., Obesity, Infertility, Contraception and Pregnancy (1998) Clinical Obesity, pp. 226-247. , Kopelman amp
Manson, J., Willett, W., Body weight and mortality among women (1995) N Engl J Med, 333, pp. 677-685
Kannel, W., D'Agostino, R., Belanger, A., Update on fibrinogen as a cardiovascular risk factor (1992) Ann Epidemiol, 2, pp. 457-466
Ditschunneit, H., Flechtner-Mors, M., Adler, G., Fibrinogen in obesity before and after weight reduction (1995) Obesity Res, 3, pp. 43-48
Van Gaal, L., Zhang, A., Steijaert, M., De Leeuw, I., Human obesity: From lipid abnormalities to lipid oxidation (1995) Int J Obesity, 19 (SUPPL. 3), pp. S21-S26
Folsom, A., Burke, G., Relation of body fatness and its distribution to cardiovascular risk factors in young black and whites. The role of insulin (1989) Am J Epidemiol, 130, pp. 911-924
Friedman, G., Selby, J., Precursors of essential hypertension: Body weight, alcohol and salt use, and parental history of hypertension (1988) Prev Med, 17, pp. 387-402
de Sousa, A. G., Cercato, C., Mancini, M. C., Halpern, A., Obesity and obstructive sleep apnea-hypopnea syndrome (2008) Obes Rev, 9 (4), pp. 340-354
Barbara, L., Sama, C., Labate, A. M. M., A population study on the prevalence of gallstone disease: The Sirmione study (1987) Hepatol, 7, pp. 913-917
Clain, D., Lefkowitch, J., Fatty liver disease in morbid obesity (1987) Gastroenterol Clin North Am, 16, pp. 239-252
Swanson, C., Brinton, L., Taylor, P., Licitra, L., Ziegler, R., Schairer, C., Body size and breast cancer risk assessed in women participating in the breast cancer detection demonstration project (1989) Am J Epidemiol, 130, pp. 1133-1141
Austin, H., Austin, J., Partridge, E., Endometrial cancer, obesity, and body fat distribution (1991) Cancer Res, 51, pp. 568-572
Demark-Wahnefried, W., Paulson, D., Body dimension differences in men with and without prostate cancer (1992) J Nat Cancer Inst, 84, pp. 1363-1364
Young, T., Palta, M., Dempsey, J., Skatrud, J., Webber, S., Badr, S., The occurence of sleep disordered breathing among middle aged adults (1993) N Engl J Med, 328, pp. 1230-1235
Young, T., Finn, L., HIa, M., Morgan, B., Palta, M., Snoring as Part of a Dose-Response Relationship Between Sleep-Disordered Breathing and Blood Pressure (1996) Sleep, 19 (10), pp. S202-S206
Mancini, M. C., Aloe, F., Obesidade, Apn ia Obstrutiva do Sono e Dist rbios Respiratorios (1998) Obesidade, Halpern A, Matos AFG, Suplicy H, Mancini MC & Zanella MT, pp. 153-170. , Ed. Lemos, S o Paulo
Cole, T. J., Freeman, J. V., Preece, M. A., Body mass index reference curves for the UK, 1990 (1995) Arch Dis Child, 73, pp. 25-29
Chan, J. M., Stampfer, M. J., Ribb, E. M., Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in man (1994) Diabetes Care, 17, pp. 961-969
Finer, N., Clinical Assessment, Investigation and Principles of Management: Realistic Weight Goals (1998) Clinical Obesity, pp. 350-376. , Kopelman amp
Wilson, G. T., Fairbu, rn, C. G., Cognitive treatments for eating disorders (1993) J Consulting Clin Psychol, 61, pp. 261-269
Tremblay, A., Buemann, B., Exercise-training, macronutrient balance and body weight control (1995) Int J Obesity, 19, pp. 79-86
Tremblay, A., Simoneau, J., Bouchard, C., Impact of exercise intensity on body fatness and skeletal muscle metabolism (1994) Metabolism, 43, pp. 814-818
(1996) Weighing the Options: Criteria for Evaluating Weight-Management Programs, , Thomas PR ed, National Academy Press: Washington DC
Long-term pharmacotherapy in the management of obesity (1996) JAMA, 276, pp. 1907-1915. , National Task Force on the Prevention and Treatment of Obesity
Tratamento, M. M. C., Farmacologico da Obesidade: Medicamentos Calorig nicos (1998) Obesidade, Halpern A, Mates AFG, Suplicy H, Mancini MC & Zanella MT, pp. 297-303. , Ed. Lemos, S o Paulo, pp
Kernan, W. N., Viscoli, C. M., Brass, L. M., Phenylpropanolamine and the Risk of Hemorrhagic Stroke (2000) N Engl J Med, 343, pp. 1826-1832
Cercato, C., Roizenblatt, V. A., Lean a, C. C., Segal, A., Lopes Filho, A. P., Mancini, M. C., Halpern, A., A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects (2009) Int J Obes, 33 (8), pp. 857-865
Connoley, I. P., Heal, D. J., Stock, M. J., A study in rats of the effects of sibutramine on food intake and thermogenesis (1995) Br J Pharmacol, 114 (SUPPL.). , 388P
Halford, J. C. G., Heal, D. J., Blundell, J. E., Effects in the rat of sibutramine on food intake and the behavioural satiety sequence (1995) Br J Pharmacol, 114 (SUPPL.). , 387P
Connoley, I. P., Uu, Y. -L., Frost, I., Thermogenic effects of sibutramine and its metabolites (1999) Br J Pharmacol, 126, pp. 1487-1495
Guerciolini, R., Mode of action of orlistat (1997) Int J Obes, 21 (SUPPL. 3), pp. S12-S23
Zhi, J., Melia, A. T., Funk, C., Metabolic profile of minimally absorbed orlistat in obese/overweight volunteers (1996) J Clin Pharmacol, 36, pp. 1006-1011
Halpern, A., Mancini, M. C., Diabesity: Are weight loss medications effective? (2005) Treat Endocrinol, 4 (2), pp. 65-74
Bray, G. A., Blackburn, G. L., Ferguson, J. M., Sibutramine produces doserelated weight loss (1999) Obesity Res, 7, pp. 189-198
Sj str m, L., Rissanen, A., Andersen, T., Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients (1998) Lancet, 352, pp. 167-172
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Role of orlistat in the treatment of obese patients with type 2 diabetes (1998) Diabetes Care, 21, pp. 1288-1294
Davidson, M. H., Hauptman, J., DiGirolamo, M., Weight control and risk factor reduction In obese subjects treated for 2 years with orlistat (1999) JAMA, 281, pp. 235-242
Garrido Jr., A. B., Matielli, J. D., Tratamento Cir rgico do Paciente Obeso (2009) Obesidade e S ndrome Metab lica para o Cl nico, pp. 267-290. , Halpern A, Mancini M. Ed. Roca, S o Paulo, pp
Sj str m, L., Narbro, K., Sj str m, C. D., Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects (2007) N Engl J Med, 357 (8), p. 23. , 741-52
Sj str m, L., Gummesson, A., Sj str m, C. D., Swedish Obese Subjects Study. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): A prospective, controlled intervention trial (2009) Lancet Oncol, 10 (7), pp. 653-662
Drug Design of Antiobesity Carbonic Anhydrase Inhibitors
The obesity is a disorder with increasing prevalence in the last decodes, which makes it a real global epidemy. The obesity is a bind of trigger factor or aggravating factor for others diseases such as diabetes mellitus, hyperlipidemia, cerebral and cardiovascular diseases, coagulation disorders, articular and degenerative diseases, hepatic esteatosis sleeping apnea and others. In patients with morbid obesity, the associated diseases have increased risk of complications with higher mortality. The medical attitude in relation to obesity have changed nowadays particularly in the recent years, improving its prevention as well as the treatment. Copyright Moreira Jr. Editora
The obesity is a disorder with increasing prevalence in the last decodes, which makes it a real global epidemy. The obesity is a bind of trigger factor or aggravating factor for others diseases such as diabetes mellitus, hyperlipidemia, cerebral and cardiovascular diseases, coagulation disorders, articular and degenerative diseases, hepatic esteatosis sleeping apnea and others. In patients with morbid obesity, the associated diseases have increased risk of complications with higher mortality. The medical attitude in relation to obesity have changed nowadays particularly in the recent years, improving its prevention as well as the treatment. Copyright Moreira Jr. Editora
Drug Design of Antiobesity Carbonic Anhydrase Inhibitors
No results. |
335 views. Last view on Monday 10 April 2023, 5:41:31
ibb.cnr.it
